Search in:

Advanced search

mAbs Volume 4, 2012 - Issue 4

Submit an article Journal homepage

Open access

749

Views

CrossRef citations to date

Altmetric

Meeting Report

7th Cancer Scientific Forum of the Cancéropôle Lyon Auvergne Rhône-Alpes

March 20–21, 2012, Lyon, France

Petrus J. Pauwels Cancéropôle CLARA; Lyon, France

Charles Dumontet INSERM 1052 CNRS 5286; Centre de Recherche de Cancerologie de Lyon; Lyon, France

Janice M. Reichert Landes Bioscience; Austin, TX USACorrespondence[email protected] [email protected]

Alain Beck Centre d’Immunologie Pierre Fabre; Saint-Julien-en-Genevois, FranceCorrespondence[email protected] [email protected]

Liliane Goetsch Centre d’Immunologie Pierre Fabre; Saint-Julien-en-Genevois, France

Nathalie Corvaïa Centre d’Immunologie Pierre Fabre; Saint-Julien-en-Genevois, France

Christian Klein Roche Pharma Research and Early Development; Roche Glycart AG; Schlieren, Switzerland

Bertrand Coiffier Hematology Department; Centre Hospitalier Lyon-Sud; Pierre-Benite, France

Beverly A. Teicher National Cancer Institute; Rockville, MD USA

show all

Pages 434-444 | Published online: 01 Jul 2012

Cite this article
https://doi.org/10.4161/mabs.20869

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413 - 5; http://dx.doi.org/10.4161/mabs.19931; PMID: 22531442
PubMed Web of Science ®Google Scholar
Reichert JM. Which are the antibodies to watch in 2012?. MAbs 2012; 4:1 - 3; http://dx.doi.org/10.4161/mabs.4.1.18719; PMID: 22327425
PubMed Web of Science ®Google Scholar
Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76 - 99; http://dx.doi.org/10.4161/mabs.3.1.13895; PMID: 21051951
PubMed Web of Science ®Google Scholar
Reichert JM. Metrics for antibody therapeutics development. MAbs 2010; 2:695 - 700; http://dx.doi.org/10.4161/mabs.2.6.13603; PMID: 20930555
PubMed Web of Science ®Google Scholar

References

Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413 - 5; http://dx.doi.org/10.4161/mabs.19931; PMID: 22531442
PubMed Web of Science ®Google Scholar
Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011; 3:415 - 6; http://dx.doi.org/10.4161/mabs.3.5.17334; PMID: 21785279
PubMed Web of Science ®Google Scholar
Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345 - 52; http://dx.doi.org/10.1038/nri2747; PMID: 20414207
PubMed Web of Science ®Google Scholar
Beck A, Senter P, Chari R. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs 2011; 3:331 - 7; http://dx.doi.org/10.4161/mabs.3.4.16612; PMID: 21691144
PubMed Web of Science ®Google Scholar
Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329 - 39; PMID: 21034674
PubMed Web of Science ®Google Scholar
Reichert JM, Beck A, Iyer H. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK. MAbs 2009; 1:394 - 416; http://dx.doi.org/10.4161/mabs.1.5.9630; PMID: 20065643
PubMedGoogle Scholar
Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 2011; 3:107 - 10; http://dx.doi.org/10.4161/mabs.3.2.14785; PMID: 21285536
PubMed Web of Science ®Google Scholar
Beck A, -Cianférani S, Van Dorsselaer A. Biosimilar, biobetter and next generation antibody characterization by mass spectrometry. Anal Chem 2012; In press http://dx.doi.org/10.1021/ac3002885; PMID: 22510259
PubMed Web of Science ®Google Scholar

References

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393 - 402; http://dx.doi.org/10.1182/blood-2009-06-225979; PMID: 20194898
PubMed Web of Science ®Google Scholar
Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118:358 - 67; http://dx.doi.org/10.1182/blood-2010-09-305847; PMID: 21444918
PubMed Web of Science ®Google Scholar
Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117:4519 - 29; http://dx.doi.org/10.1182/blood-2010-07-296913; PMID: 21378274
PubMed Web of Science ®Google Scholar
Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108:12669 - 74; http://dx.doi.org/10.1073/pnas.1108455108; PMID: 21768335
PubMed Web of Science ®Google Scholar
Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011; 10:178 - 85; http://dx.doi.org/10.1158/1535-7163.MCT-10-0385; PMID: 21220500
PubMed Web of Science ®Google Scholar
Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012; 119:3523 - 33; http://dx.doi.org/10.1182/blood-2011-12-395541; PMID: 22354003
PubMed Web of Science ®Google Scholar
Jak M, van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, Umana P, et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood 2011; 118:5178 - 88; http://dx.doi.org/10.1182/blood-2011-01-331702; PMID: 21948297
PubMed Web of Science ®Google Scholar
Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012; 119:5118 - 25; http://dx.doi.org/10.1182/blood-2012-02-408773; PMID: 22438256
PubMed Web of Science ®Google Scholar
Salles G, Morschhauser F, Lamy T, Milpied NJ, Thieblemont C, Tilly H, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119:5126 - 32; http://dx.doi.org/10.1182/blood-2012-01-404368; PMID: 22431570
PubMed Web of Science ®Google Scholar
Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187 - 92; http://dx.doi.org/10.1073/pnas.1019002108; PMID: 21690412
PubMed Web of Science ®Google Scholar
Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677 - 81; http://dx.doi.org/10.1038/nbt0798-677; PMID: 9661204
PubMed Web of Science ®Google Scholar

References

Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84:2457 - 66; PMID: 7522629
PubMed Web of Science ®Google Scholar
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825 - 33; PMID: 9704735
PubMed Web of Science ®Google Scholar
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235 - 42; http://dx.doi.org/10.1056/NEJMoa011795; PMID: 11807147
PubMed Web of Science ®Google Scholar
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164 - 74; http://dx.doi.org/10.1016/S0140-6736(10)61381-5; PMID: 20888994
PubMed Web of Science ®Google Scholar
Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706 - 14; http://dx.doi.org/10.1093/jnci/djk152; PMID: 17470738
PubMed Web of Science ®Google Scholar
Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87:189 - 95; PMID: 11836170
PubMed Web of Science ®Google Scholar
Dörner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009; 5:433 - 41; http://dx.doi.org/10.1038/nrrheum.2009.141; PMID: 19581902
PubMed Web of Science ®Google Scholar
Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:409 - 12; http://dx.doi.org/10.1136/ard.2009.109041; PMID: 19596693
PubMed Web of Science ®Google Scholar
Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011; 17:6389 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-11-1417; PMID: 22003066
PubMed Web of Science ®Google Scholar
Derby L, Czuczman MS. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncol 2011; 7:963 - 79; http://dx.doi.org/10.2217/fon.11.79; PMID: 21823892
PubMed Web of Science ®Google Scholar
Cartron G, Trappe RU, Solal-Céligny P, Hallek M. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011; 17:19 - 30; http://dx.doi.org/10.1158/1078-0432.CCR-10-1292; PMID: 21208903
PubMed Web of Science ®Google Scholar
Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma. Haematologica 2011; 96:567 - 73; http://dx.doi.org/10.3324/haematol.2010.037390; PMID: 21173095
PubMed Web of Science ®Google Scholar
Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362 - 71; PMID: 16785532
PubMed Web of Science ®Google Scholar
Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824 - 31; http://dx.doi.org/10.1182/blood-2008-04-153189; PMID: 18799723
PubMed Web of Science ®Google Scholar
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377:42 - 51; http://dx.doi.org/10.1016/S0140-6736(10)62175-7; PMID: 21176949
PubMed Web of Science ®Google Scholar
Kluin-Nelemans H, Hoster E, Hermine O, et al. Induction and maintenance therapy in elderly patients with mantle cell lymphoma. Double-randomized trial by the European Mantle Cell Lymphoma Network. N Engl J Med 2012; In press
PubMedGoogle Scholar
Nightingale G. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann Pharmacother 2011; 45:1248 - 55; http://dx.doi.org/10.1345/aph.1P780; PMID: 21896924
PubMed Web of Science ®Google Scholar
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393 - 402; http://dx.doi.org/10.1182/blood-2009-06-225979; PMID: 20194898
PubMed Web of Science ®Google Scholar
Patz M, Isaeva P, Forcob N, Müller B, Frenzel LP, Wendtner CM, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152:295 - 306; http://dx.doi.org/10.1111/j.1365-2141.2010.08428.x; PMID: 21155758
PubMed Web of Science ®Google Scholar
Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall’Acqua W, et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011; 155:426 - 37; http://dx.doi.org/10.1111/j.1365-2141.2011.08857.x; PMID: 21902688
PubMed Web of Science ®Google Scholar
Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007; 26:3704 - 13; http://dx.doi.org/10.1038/sj.onc.1210370; PMID: 17530024
PubMed Web of Science ®Google Scholar
Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27:4371 - 7; http://dx.doi.org/10.1200/JCO.2008.21.3017; PMID: 19636010
PubMed Web of Science ®Google Scholar
Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 2011; 22:1595 - 600; http://dx.doi.org/10.1093/annonc/mdq635; PMID: 21212158
PubMed Web of Science ®Google Scholar
Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103:2920 - 4; http://dx.doi.org/10.1182/blood-2003-10-3389; PMID: 15070664
PubMed Web of Science ®Google Scholar
Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101:4267 - 72; http://dx.doi.org/10.1182/blood-2002-09-2802; PMID: 12543862
PubMed Web of Science ®Google Scholar
O’Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res 2009; 15:2514 - 22; http://dx.doi.org/10.1158/1078-0432.CCR-08-1254; PMID: 19293260
PubMed Web of Science ®Google Scholar
Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25:2764 - 9; http://dx.doi.org/10.1200/JCO.2006.07.8972; PMID: 17515574
PubMed Web of Science ®Google Scholar
Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146:171 - 9; http://dx.doi.org/10.1111/j.1365-2141.2009.07740.x; PMID: 19466965
PubMed Web of Science ®Google Scholar
d’Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010; 150:565 - 73; http://dx.doi.org/10.1111/j.1365-2141.2010.08298.x; PMID: 20629661
PubMed Web of Science ®Google Scholar
Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109:4655 - 62; http://dx.doi.org/10.1182/blood-2006-12-062877; PMID: 17311990
PubMed Web of Science ®Google Scholar
Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30:837 - 42; http://dx.doi.org/10.1200/JCO.2011.37.3472; PMID: 22312108
PubMed Web of Science ®Google Scholar
Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol 2006; 33:Suppl 5 S44 - 52; http://dx.doi.org/10.1053/j.seminoncol.2006.01.029; PMID: 16720203
PubMed Web of Science ®Google Scholar
Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin’s lymphoma: from the ‘magic bullets’ to ‘radioactive magic bullets’. Yale J Biol Med 2011; 84:391 - 407; PMID: 22180677
PubMedGoogle Scholar

References

Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011; 17:6389 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-11-1417; PMID: 22003066
PubMed Web of Science ®Google Scholar
Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009; 9:982 - 1004; http://dx.doi.org/10.2174/156800909790192365; PMID: 20025606
PubMed Web of Science ®Google Scholar
Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011; 17:6417 - 27; http://dx.doi.org/10.1158/1078-0432.CCR-11-0486; PMID: 22003069
PubMed Web of Science ®Google Scholar
Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res 2011; 17:6428 - 36; http://dx.doi.org/10.1158/1078-0432.CCR-11-0488; PMID: 22003070
PubMed Web of Science ®Google Scholar
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011; 17:6437 - 47; http://dx.doi.org/10.1158/1078-0432.CCR-11-0762; PMID: 22003071
PubMed Web of Science ®Google Scholar
Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011; 17:6448 - 58; http://dx.doi.org/10.1158/1078-0432.CCR-11-0485; PMID: 22003072
PubMed Web of Science ®Google Scholar
Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 2011; 17:6406 - 16; http://dx.doi.org/10.1158/1078-0432.CCR-11-0483; PMID: 22003068
PubMed Web of Science ®Google Scholar
Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011; 17:6398 - 405; http://dx.doi.org/10.1158/1078-0432.CCR-11-0487; PMID: 22003067
PubMed Web of Science ®Google Scholar
Rouleau C, Smale R, Fu Y-S, Hui G, Wang F, Hutto E, et al. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. Int J Oncol 2011; 39:73 - 89; PMID: 21537839
PubMed Web of Science ®Google Scholar
Rouleau C, Curiel M, Weber W, Smale R, Kurtzberg L, Mascarello J, et al. Comprehensive assessment of endosialin protein expression in human cancer: therapeutic implications for synovial sarcoma, fibrosarcoma, malignant fibrous histiocytoma and osteosarcoma. Clin Cancer Res 2008; 14:7223 - 36; http://dx.doi.org/10.1158/1078-0432.CCR-08-0499; PMID: 19010839
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

7th Cancer Scientific Forum of the Cancéropôle Lyon Auvergne Rhône-Alpes

March 20–21, 2012, Lyon, France

References

References

References

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

7th Cancer Scientific Forum of the Cancéropôle Lyon Auvergne Rhône-Alpes

March 20–21, 2012, Lyon, France

References

References

References

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date